Nautilus Biotechnolgy (NAUT) AI Stock Analysis

• Market Cap: $93.48M
• Dividend Yield: N/A
• Average Volume (3M): 433.61K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.03
• Revenue Growth: N/A
• EPS Growth: -1.20%
• Country: US
• Employees: 134
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -0.13
• Shares Outstanding: 126,148,470
• 10 Day Avg. Volume: 172,386
• 30 Day Avg. Volume: 433,609
• PEG Ratio: -0.39
• Price to Book (P/B): 0.49
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.64
• Enterprise Value/Market Cap: 0.93
• Enterprise Value/Revenue: 5.29
• Enterprise Value/Gross Profit: -27.09
• Enterprise Value/Ebitda: -0.29
• 1Y Price Target: $2.75
• Price Target Upside: 271.62% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 41 Neutral
• Price Target: ―

Nautilus Biotechnology's score reflects its early-stage status with high operational losses and zero revenue, typical for biotech firms focused on R&D. While its strong cash reserves and low leverage offer some stability, persistent losses and slow pharma partnerships pose significant risks. Technical indicators suggest a bearish trend, but the earnings call highlighted positive advancements in proteomics and cost efficiencies, offering a cautiously optimistic outlook.

Positive Factors

Cash Management

Ongoing cash management efforts are encouraging, as well as the progress towards a differentiated proteomics offering.

Operational Efficiency

Cost management and a 16% reduction in force should enable the cash runway to extend to 2027.

Technological Development

At close to a $0 EV with 3+ years of cash, the tech development further along than at any time in the past, addressing a large market with a differentiated approach, and a seasoned life science management team, the current stock price presents an interesting level.

Negative Factors

Commercial Launch Delays

NAUT traded down nearly (20%) after another commercial launch timeline delay, this one a push out to late 2026.

Internal Milestones

The company was behind on internal milestones with respect to a major broadscale goal of quantifying a significant number of proteins from a complex sample.

Timeline Modifications

Commercial launch now expected in late-2026, delayed from late 2025, due to modifications needed on the assay configuration and surface chemistry.

Nautilus Biotechnolgy Business Overview & Revenue Model

Company Description

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.

How the Company Makes Money

Nautilus Biotechnology generates revenue primarily through the commercialization of its proteomics platform. The company offers its technology to pharmaceutical companies, academic institutions, and research organizations, which use it to conduct detailed protein analysis. Key revenue streams include the sale of instruments, consumables, and related services required to operate the platform. Additionally, Nautilus may engage in strategic partnerships and collaborations with other entities in the biotech and pharmaceutical industries, which can provide further revenue through joint research projects, licensing agreements, and milestone payments based on the successful achievement of specific research or development goals.

Nautilus Biotechnolgy Financial Statement Overview

Summary

Nautilus Biotechnology is in an early growth phase with consistent zero revenue and significant net losses, typical for biotech startups. Strong cash reserves and low leverage offer some financial stability, but the ongoing operational losses and cash outflows pose significant risks.

Income Statement

Nautilus Biotechnology has consistently reported zero revenue, reflecting its early-stage development status typical for biotech firms. The company faces significant net losses, with a negative net profit margin and no gross profit. Revenue growth is non-existent, while operating expenses remain high, adversely affecting EBIT and EBITDA margins.

Balance Sheet

The balance sheet shows a relatively strong equity position with a consistent decrease in stockholders' equity over recent years, reflecting ongoing losses. The debt-to-equity ratio is favorable, indicating low leverage, but the negative equity in earlier years signals financial instability. The equity ratio is reasonably high, suggesting a good proportion of assets financed by equity.

Cash Flow

The cash flow statement reveals negative free cash flow and operating cash flow, reflecting high cash burn typical for biotech startups. The free cash flow to net income ratio is negative, indicating cash outflows exceed inflows. However, substantial cash reserves provide a buffer against short-term financial challenges.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	-5.71M	-3.42M	-2.84M	-2.35M
EBITDA	-64.43M	-74.30M	-60.20M	-47.66M	-13.40M
Net Income	-70.78M	-63.67M	-57.92M	-50.31M	-15.62M
Balance Sheet
Total Assets	242.74M	305.56M	350.05M	398.45M	85.01M
Cash, Cash Equivalents and Short-Term Investments	129.89M	173.42M	184.47M	345.73M	76.74M
Total Debt	30.48M	34.63M	30.33M	30.03M	4.78M
Total Liabilities	34.01M	40.21M	35.13M	34.87M	114.73M
Stockholders Equity	208.73M	265.35M	314.92M	363.58M	-29.72M
Cash Flow
Free Cash Flow	-61.27M	-54.15M	-48.13M	-41.51M	-14.92M
Operating Cash Flow	-59.15M	-51.71M	-45.81M	-39.24M	-14.00M
Investing Cash Flow	66.25M	-43.73M	-25.74M	-138.96M	-25.28M
Financing Cash Flow	1.14M	368.00K	562.00K	327.45M	75.90M

Nautilus Biotechnolgy Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.74
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NAUT, the sentiment is Negative. The current price of 0.74 is below the 20-day moving average (MA) of 0.76, below the 50-day MA of 0.76, and below the 200-day MA of 1.48, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 48.30 is Neutral, neither overbought nor oversold. The STOCH value of 24.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NAUT.

Nautilus Biotechnolgy Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	60 Neutral	HK$16.88B	5.55	-7.44%	3.12%	11.55%	-28.15%
SEER	55 Neutral	$126.52M	―	-24.73%	―	-1.02%	-8.59%
OBIO	49 Neutral	$122.60M	―	-179.12%	―	30.23%	-21.32%
NAUT	41 Neutral	$93.48M	―	-30.93%	―	―	-1.20%
TIL	34 Underperform	$186.56M	―	-44.50%	―	―	52.54%
NMRA	33 Underperform	$305.70M	―	-79.05%	―	―	-0.42%

Nautilus Biotechnolgy Corporate Events

Nautilus Biotechnology Announces Board Changes for 2025

Nautilus Biotechnology announced changes in its board of directors for the 2025 annual meeting, with Vijay Pande and Michael Altman stepping down, and Matthew McIlwain transitioning to a Class I director to maintain board balance. The company also reported its financial results for the fourth quarter and fiscal year 2024, highlighting a slight increase in operating expenses and a net loss compared to the previous year. Nautilus plans to launch its proteome analysis platform in late 2026 and has reduced its workforce by 16% to align resources with development goals, aiming to extend its cash runway through 2027.